CN104013770A - Pharmaceutical composition for treating arthritis and osteocarcinoma - Google Patents
Pharmaceutical composition for treating arthritis and osteocarcinoma Download PDFInfo
- Publication number
- CN104013770A CN104013770A CN201410279713.6A CN201410279713A CN104013770A CN 104013770 A CN104013770 A CN 104013770A CN 201410279713 A CN201410279713 A CN 201410279713A CN 104013770 A CN104013770 A CN 104013770A
- Authority
- CN
- China
- Prior art keywords
- parts
- pharmaceutical composition
- osteocarcinoma
- radix
- effect
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a pharmaceutical composition for treating arthritis and osteocarcinoma. The pharmaceutical composition is prepared from the following raw materials in parts by weight: 12-24 parts of radix salviae miltiorrhizae, 12-24 parts of angelica sinensis, 12-24 parts of ligusticum wallichii, 12-24 parts of safflower carthamus, 12-24 parts of semen strychni, 12-24 parts of radix angelicae pubescentis, 12-24 parts of radix dipsaci, 12-24 parts of thunder god vine, 12-24 parts of radix aconiti carmichaeli, 9-21 parts of cynanchum paniculatum, 9-21 parts of rhizoma drynariae, 9-21 parts of fructus psoraleae, 9-21 parts of spina gleditsiae, 9-21 parts of astragalus membranaceus, 9-21 parts of radix notoginseng, 9-21 parts of asarum, 9-21 parts of calomel, 9-21 parts of calcium powder, 9-21 parts of magnesium powder and 9-21 parts of air potato. The invention discloses a pharmaceutical composition with relatively good effect on treating arthritis and osteocarcinoma and an application thereof.
Description
Technical field
The present invention relates to technical field of Chinese medicines, be specifically related to the pharmaceutical composition of a kind for the treatment of of arthritis and osteocarcinoma.
Background technology
Arthritis general reference occurs in the inflammatory diseases of human synovial and surrounding tissue thereof, tens of kinds be can be divided into, rheumatic arthritis, rheumatoid arthritis, osteoarthritis, gouty arthritis, ankylosing spondylitis, reactive arthritis, infective arthritis etc. comprised.Arthritic cause of disease complexity, mainly relevant with the factor such as inflammation, autoimmune response, infection, metabolism disorder, wound, degeneration.
Cancer (Cancer), also claims malignant tumor (Malignant neoplasm), serves as reasons and controls the not normal and disease that causes of growth and proliferation of cell mechanism.Cancerous cell except grow out of control, arround also can local invading, normal structure is even transferred to other parts of health via body-internal-circulation system or lymphsystem.Cancer is the general designation of a large class malignant tumor.The feature of cancerous cell be unrestrictedly, hypertrophy without end, the nutrient substance in patient body is consumed in a large number; Cancerous cell discharges multiple toxin, makes human body produce series of symptoms; Cancerous cell also can be transferred to whole body growth and breeding everywhere, cause that human body is become thin, unable, anemia, inappetence, heating and serious organ function impaired etc.Cancer (malignant tumor) also can disorganize, the 26S Proteasome Structure and Function of organ, causes downright bad hemorrhage concurrent infection, and patient is finally dead due to organ failure.
Bone tumor is the tumor that betides skeleton or its affiliated group (blood vessel, nerve, bone marrow etc.), is commonly encountered diseases.With other tissue of health, its definite etiology unknown; Bone tumor has optimum, and pernicious divides, and benign bone tumour easily effects a radical cure, prognosis bona, and rapidly, prognosis is not good in malignant bone tumor development, and mortality rate is high, there is no so far satisfied Therapeutic Method.Malignant bone tumor can be former, can be also secondary, and from the malignant tumor of other tissue in body or organ, through blood circulation, lymphsystem is transferred to skeleton or directly invades skeleton.Also have a class disease damage to claim tumor-like lesion, Tumor-like Lesion organize the feature without tumor cell form, but its ecological and behavior all has the destructiveness of tumor, generally limitation, easily effects a radical cure.
Osteocarcinoma belongs to the category such as " bone tuberculosis ", " osteoma " in the traditional Chinese medical science.Osteocarcinoma symptom mainly contains pain, anemia, malaise has feeling of numbness, malnutrition and pathologic to change fracture etc.Local pain and tenderness are common sympton, can occur with lump simultaneously or first occur, are intermittent dull pain, gradually become afterwards persistence severe pain.Superficial place can touch expandable bone distortion and soft mass, and skin is kermesinus, and Pi Wen increases, and forms in a short time larger lump, dysfunction, skeleton deformity etc.The Chinese traditional treatment of osteocarcinoma combines in operation, radiotherapy, chemotherapy, can improve curative effect.
At present, to arthritic treatment, doctor trained in Western medicine adopts medicine or surgical operation, and conventional medicine is as follows: (1) NSAID (non-steroidal anti-inflammatory drug) can suppress the synthetic of prostaglandin and produce rapidly anti-inflammatory analgesic effect, there is better effects to removing pain, but can not change the course of disease of disease.Conventional clinically have glucosamine hydrochloride granule, ibuprofen, penicillamine, diclofenac, aspirin, an indomethacin etc.(2) act on slowly antirheumatic and be used for rheumatoid arthritis and seronegative spondyloanthropathy.The state of an illness is had to certain control action but onset is slower.Conventional have golden mixture (intramuscular injection or oral), penicillamine, sulfasalazine, a chloroquine etc.(3) cell toxicity medicament produces immunosuppressive action by different approaches.Conventional have cyclophosphamide, methotrexate, a Jin Duchun etc.They are systemic lupus erythematosus (sle), rheumatoid arthritis and vasculitic Second line Drug often, though side effect is more and more serious, has more afterwards a very large effect to what improve these diseases.(4) adrenocortical hormone is antiinflammatory, Claritin, improved significantly the connective tissue diseases such as systemic lupus erythematosus (sle) more after, but can not effect a radical cure these diseases.Its numerous side effect strengthens with dosage and extends the course for the treatment of to be increased, therefore will weigh its curative effect and side effect and careful in selecting in when application.(5) streptococcal infection such as antibiotic can cause the arthritis performance of rheumatic fever, it is the most effective medicine of controlling streptococcal infection that acute stage is used penicillin, acute rheumatic fever patient's life-time service long acting antibiotic is to prevent the generation of rheumatic carditis at a specified future date, being grown up prevent is shorter than 5 years, and child is at least maintained to 18 years old.Tuberculous arthritis, fungoid arthritis need active and effective tuberculosis or antifungal drug treatment.(6) treatment of gouty arthritis comprises that the Drug therapy of acute stage comprises heavy dose of NSAID (non-steroidal anti-inflammatory drug) or colchicine and the treatment of paracmastic uric acid resisting.Uric acid resisting drug main will comprise the allopurinol that suppresses uricopoiesis class and the benzbromarone that promotes urate excretion class.Surgical intervention mainly comprises that joint puncture, synovectomy, joint replacement, joint are orthopedic, joint fusion, bone marrow transplantation, immuno biological therapy etc.Surgical effect is better, but general expenses are higher, and patient's burden is heavier.
At present, treatment osteocarcinoma, doctor trained in Western medicine generally adopts operation, chemotherapy, radiotherapy, and the toxic and side effects that Radiotherapy chemotherapy produces is to human body infringement greatly, patient often can not get satisfied effect, but causes on the contrary the adverse consequencess such as health immunologic hypofunction.For avoiding western medical treatment defect, in China, medical circles release the scheme that treats with herbal composite treatment cancer.Chinese traditional treatment cancer is approved by domestic and international Medical Technologist now widely, the effect of Chinese traditional treatment cancer that a large amount of clinical trials and scientific research are verified.Such as Chinese patent CN102114199B, disclose a kind of Chinese medicine for the treatment of osteocarcinoma, this Chinese medicine is made up of the crude drug of following parts by weight: Spina Gleditsiae 2-5 part, Folium Persicae 0.5-2 part, Herba Violae 2-5 part, Rhizoma Imperatae 0.5-2 part, Radix Polygoni Multiflori 0.5-2 part, mediocre fragrant 0.1-1 part and Ganoderma Lucidum 0.5-2 part.
The traditional Chinese medical science is endless to the research of cancer, and exploitation can be simultaneously very necessary for the Traditional Chinese medicine composition of arthritis and osteocarcinoma.
Summary of the invention
The technical problem to be solved in the present invention is to provide a kind for the treatment of of arthritis and the good pharmaceutical composition of osteocarcinoma effect.
In pharmaceutical composition of the present invention, the consumption of each component is that inventor draws through a large amount of practice summaries, is made up of the raw material of following weight parts:
Preferably, it is to be made up by weight of following raw materials according:
More preferably, it is to be made up by weight of following raw materials according:
The medically acceptable dosage forms such as the preferred pill of dosage form of pharmaceutical composition of the present invention, tablet, dispersible tablet, their preparation method, supplementary product consumption are undertaken by existing common process.
The present invention also comprises the application of aforementioned pharmaceutical compositions in preparation treatment of arthritis and osteocarcinoma medicine.
In pharmaceutical composition prescription of the present invention:
Radix Salviae Miltiorrhizae--there is removing heat from blood and promoting blood circulation, the dredging collateral effect of having one's ideas straightened out;
Radix Angelicae Sinensis--the effect of invigorating blood circulation that having enriches blood;
Rhizoma Chuanxiong--there is blood-activating and qi-promoting, removing obstruction in the collateral to relieve pain effect;
Semen Strychni--there is mass dissipating and swelling eliminating analgesic effect;
Radix Angelicae Pubescentis--there is expelling pathogenic wind and eliminating dampness, the bone strengthening effect of invigorating blood circulation;
Radix Dipsaci--there is liver and kidney tonifying, strong rigidity of soft tissues bone effect;
Radix Tripterygii Wilfordii--there is promoting blood circulation to remove obstruction in the collateral, subduing swelling and detoxicating effect;
Radix Aconiti Lateralis Preparata--there is contrary returning to life from the nether world, the QI and blood collapse effect rescued;
Radix Cynanchi Paniculati--there is removing heat from blood, softening the hard mass toxin expelling, anticancer swollen effect;
Fructus Psoraleae--there is the kidney warming bone strengthening, the empty effect of the kidney invigorating;
Spina Gleditsiae--there is mass dissipating and swelling eliminating, anticancer toxin expelling effect;
The Radix Astragali--there is QI invigorating circulation of qi promoting, subduing swelling and detoxicating effect;
Radix Notoginseng--there is promoting blood circulation and cooling blood, detumescence, analgesic effect;
Herba Asari--there is YANG invigorating analgesic effect;
Calomelas--there is removing the necrotic tissue and promoting granulation, antitumaous effect;
Rhizoma Dioscoreae Bulbiferae--there is suppuration eliminating stagnation, anticancer swollen effect;
Calcium powder--there is the bone of enhancing rockiness, anti-inflammatory effect;
Magnesium powder--there is strengthening the tendons and bones effect;
Pharmaceutical composition of the present invention is at Calomelas on the basis as anticancer pharmaceutical composition, add other components, compare simple use Calomelas, pharmaceutical composition of the present invention also have invigorate blood circulation, removing heat from blood, dredging collateral is had one's ideas straightened out, evacuation of pus blood stasis dispelling, softening the hard mass scrofula, dispersing tumor are anticancer, improve immunologic function, repair bone density, reduction sclerotin calcium magnesium element, promote that bone marrow is anticancer, heat-clearing and toxic substances removing, anti-inflammatory and anticancer, with poison effect for cancer.For whole body, adjustment more has superiority, and early treatment can control symptom, improves symptom, improve long-term trend, can significantly increase bone density, controls the pathological changes of bone and improves pain.
Detailed description of the invention
With specific embodiment, the invention will be further described below, but the present invention is not limited to these embodiment.
Embodiment 1
By drying above-mentioned raw materials rear pulverizing, cross 80 mesh sieves, add making pellets by mixing medical powder with honey, obtain pill.
Embodiment 2
Take above each raw material by proportional quantity, decoct with water twice, add for the first time 7 times of water gagings, decoct 1.5 hours, add for the second time 8 times of water gagings, decoct 1.5 hours, collecting decoction, filters, and filtrate is concentrated into relative density be 1.30 extractum of (70 DEG C time survey), add appropriate cane sugar powder, routinely the agent of technique granulation.
Embodiment 3
Above-mentioned raw materials is mixed, and drying rear pulverizing, crosses 80 mesh sieves, obtains powder.
Embodiment 4
Take above each raw material by proportional quantity, decoct with water twice, add for the first time 7 times of water gagings, decoct 1.5 hours, add for the second time 8 times of water gagings, decoct 1.5 hours, collecting decoction, filters, filtrate is concentrated into relative density be 1.30 extractum of (70 DEG C time survey), the magnesium stearate adjuvant that adds conventional amount used, technique is made tablet routinely, 0.5 part/sheet of specification.
Embodiment 5
Take above each raw material by proportional quantity, decoct with water twice, add for the first time 7 times of water gagings, decoct 1.5 hours, add for the second time 8 times of water gagings, decoct 1.5 hours, collecting decoction, filters, filtrate is concentrated into relative density be 1.30 extractum of (70 DEG C time survey), add the magnesium stearate adjuvant of conventional amount used, make capsule, 0.5g/ grain.
Experimental example: the inhibitory action of pharmaceutical composition of the present invention to cancerous cell
1, experiment material: pharmaceutical composition prepared by the embodiment of the present invention 3, embodiment 5.
Experiment place: the Guangxi Qinzhou hospital of traditional Chinese hospital.
2, tumor cell line: osteocarcinoma cell U2OS, use RPMI-1649 culture fluid, 37 DEG C, 5%C0
2, relative humidity 100% is cultivated, and attached cell 0.25% trypsinization goes down to posterity.
3, the inhibitory action of method MTT colorimetric method for determining extract to growth of tumour cell.The trophophase cell of taking the logarithm, is mixed with cell suspension, suspension cell 1X10 with fresh RPMI-1640 culture fluid
5individual/ml attached cell 0.8X10
5individual/ml.Suspension cell is inoculated in 96 well culture plates after adding respectively variable concentrations Experimental agents; Attached cell is first inoculated in 96 well culture plates, and every hole 90 μ l, add respectively variable concentrations Experimental agents after 24h.Final volume is that every hole 100 μ l and every group are established 3 parallel holes, establishes altogether 4 groups: be subject to reagent group T (culture fluid+cell suspension+variable concentrations is subject to reagent), negative control group N (culture fluid+cell suspension), medicine color matched group TC (culture fluid+variable concentrations is subject to reagent), blank group B (culture fluid+normal saline).Tested concentration is followed successively by 10 μ g/m1,30 μ g/m1,50 μ g/ml.Put 37 DEG C, 5%C0
2in incubator, cultivate after 72h, after adding the 10 μ l concussions of MTT solution to mix to every hole, continue to cultivate 4h, add SDS90 μ l to stop cultivating, 37 DEG C are spent the night, then under room temperature, on micro oscillator, shake 10min, microplate reader is measured the absorbance (OD value) at 570nm wavelength place, and experiment repeats 3 times.
Calculate as follows growth inhibition ratio:
Growth inhibition ratio (%)=[(N group OD average-B group OD average)-(T group OD average-TC group OD average)]/[N group OD average-B group OD average] X100%.
4, medicine the results are shown in Table 1 to the suppression ratio of osteocarcinoma cell U2OS.
Table 1: to the suppression ratio result of U2OS
Result shows, pharmaceutical composition prepared by embodiment 3, embodiment 5 has inhibitory action to the propagation of U2OS cell, and embodiment 5 curative effects are better than embodiment 3.
Clinical effectiveness
For many years, medicine composite for curing clinical observation of the present invention, all obtains promising result, as follows:
1, physical data
414 routine patients all hitch institute and out-patient.Wherein male 228 examples, female's 186 examples; The oldest 72 years old, minimum 26 years old; The course of disease is the longest 4 years, the shortest half a year.
Take the capsule that the embodiment of the present invention 5 obtains, every day 3 times, each 2,30 days courses for the treatment of, take 4 courses for the treatment of.
2, diagnostic criteria
" the new Chinese medicine clinical guidance principle " diagnostic criteria of promulgating with reference to Ministry of Public Health is made a definite diagnosis.
3, criterion of therapeutical effect
Effective: sign and symptom are improved completely, focus disappears substantially or completely, without shifting, without diffusion;
Effective: sign and symptom are significantly improved, and focus is significantly improved;
Invalid: sign is without change, and symptom is as front.
4, therapeutic outcome
Claims (4)
1. a pharmaceutical composition for treatment of arthritis and osteocarcinoma, is characterized in that: this pharmaceutical composition is to be made up of the raw material of following weight parts:
2. the pharmaceutical composition for the treatment of of arthritis according to claim 1 and osteocarcinoma, is characterized in that: this pharmaceutical composition is to be made up of the raw material of following weight parts:
3. the pharmaceutical composition for the treatment of of arthritis according to claim 1 and osteocarcinoma, is characterized in that: this pharmaceutical composition is to be made up of the raw material of following weight parts:
4. the application of the pharmaceutical composition described in any one in the medicine of preparation treatment of arthritis and osteocarcinoma in claim 1-3.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410279713.6A CN104013770A (en) | 2014-06-20 | 2014-06-20 | Pharmaceutical composition for treating arthritis and osteocarcinoma |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410279713.6A CN104013770A (en) | 2014-06-20 | 2014-06-20 | Pharmaceutical composition for treating arthritis and osteocarcinoma |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104013770A true CN104013770A (en) | 2014-09-03 |
Family
ID=51430953
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410279713.6A Pending CN104013770A (en) | 2014-06-20 | 2014-06-20 | Pharmaceutical composition for treating arthritis and osteocarcinoma |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104013770A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106039236A (en) * | 2016-07-29 | 2016-10-26 | 天津康源益健生物科技有限公司 | Traditional Chinese medicine preparation for treating bone cancer and improving immunity, and preparation method of traditional Chinese medicine preparation |
-
2014
- 2014-06-20 CN CN201410279713.6A patent/CN104013770A/en active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106039236A (en) * | 2016-07-29 | 2016-10-26 | 天津康源益健生物科技有限公司 | Traditional Chinese medicine preparation for treating bone cancer and improving immunity, and preparation method of traditional Chinese medicine preparation |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101703708B (en) | Chinese medicinal preparation for treating rheumatoid arthritis and gout, and preparation method thereof | |
| CN104491740B (en) | A kind of Chinese medicine composition for treating liver cancer and preparation method thereof | |
| CN101849999B (en) | Chinese medicinal composition for treating pelvic inflammation and preparation method thereof | |
| CN101590168B (en) | Traditional Chinese medicine combination for treating gout and preparation method thereof | |
| CN101590184B (en) | Traditional Chinese medicine combination for treating gout and preparation method thereof | |
| CN103285119A (en) | Chinese medicine composition for treating autoimmune liver disease, and preparation method thereof | |
| CN101584758A (en) | A kind of pharmaceutical composition for the treatment of kidney deficiency | |
| CN103520633B (en) | Processing method of anticancer blood-circulation activating and mass disintegrating ointment | |
| CN103157014B (en) | Miao medicine for treating tumors | |
| CN101590167B (en) | Traditional Chinese medicine combination for treating gout and preparation method thereof | |
| CN104013770A (en) | Pharmaceutical composition for treating arthritis and osteocarcinoma | |
| CN104013816A (en) | Pharmaceutical composition for treating esophagus cancer | |
| CN103977256A (en) | Medicine composition for treating cancer | |
| CN101590166B (en) | Traditional Chinese medicine combination for treating gout and preparation method thereof | |
| CN100391512C (en) | Medicine for promoting blood circulation, dispersing blood clots, eliminating swelling and pain, and dispelling wind and wetness | |
| CN104107288A (en) | Sinew-relaxing collateral-activating pill | |
| CN102225182A (en) | Traditional Chinese preparation capable of inhibiting tumor and enhancing immunity and preparation method thereof | |
| CN1857660A (en) | Chinese medicine composition for treating lung cancer, esophagus carcinoma and throat cancer | |
| CN103735635A (en) | Medicinal composition for treating cancers and leukemia | |
| CN101024029B (en) | Medicine for treating bony arthritis, rheumatism arthritis | |
| CN103830679B (en) | A kind of medicine and application thereof for the treatment of irritable bowel syndrome | |
| CN104013916A (en) | Pharmaceutical composition for treating metrocarcinoma | |
| CN102266384B (en) | Analgesic medicinal preparation for treating abdominal mass and preparation method thereof | |
| CN1569085A (en) | Pharmaceutical composition for treating rheumatic arthritis and rheumatoid arthritis | |
| CN101028421A (en) | Chinese medicine for treating chronic kidney failure |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20140903 |